Vireo Growth (VREOF) Net Cash Flow (2020 - 2026)
Vireo Growth (VREOF) reported Net Cash Flow of $15.3 million for Q1 2026, up 383.33% on a YoY basis from $3.2 million in Q1 2025, and up 208.74% sequentially from $5.0 million in Q4 2025.
Vireo Growth (VREOF) Net Cash Flow (2020 - 2026) Analysis & Trends
Vireo Growth (VREOF) has 7 years of Net Cash Flow data on file, last reported at $15.3 million in Q1 2026.
- For the quarter ending Q1 2026, Net Cash Flow rose 383.33% year-over-year to $15.3 million; the trailing twelve-month figure through Mar 2026 stood at $51.6 million (down 29.91% YoY), and the FY2025 full-year result was $30.9 million, down 59.16% from the prior year.
- Net Cash Flow advanced to $15.3 million in Q1 2026, from $5.0 million in the prior quarter.
- In the past five years, Net Cash Flow ranged from a high of $84.3 million in Q4 2024 to a low of -$6.7 million in Q4 2022.
- A 5-year average of $7.2 million and a median of $2.0 million in 2023 frame the typical range for Net Cash Flow.
- Peak annual rise in Net Cash Flow reached 3059.99% in 2024, while the deepest fall reached 302.53% in 2024.
- Tracing VREOF's Net Cash Flow over 5 years: stood at -$6.7 million in 2022, then jumped by 139.87% to $2.7 million in 2023, then jumped by 3059.99% to $84.3 million in 2024, then sank by 94.12% to $5.0 million in 2025, then jumped by 208.74% to $15.3 million in 2026.
- Business Quant data shows VREOF's Net Cash Flow at $15.3 million in Q1 2026, $5.0 million in Q4 2025, and $11.3 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 202.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | -526.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 711.50 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | -277.40 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 461.90 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | -446.50 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | -112.00 Mn |
| 10 | Vireo Growth | 10.57 Bn | 10.41 Bn | 59.30 Mn | 15.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 15.30 Mn |
| Mar 31, 2026 | 15.30 Mn |
| Dec 31, 2025 | 4.96 Mn |
| Dec 31, 2025 | 4.96 Mn |
| Sep 30, 2025 | 11.35 Mn |
| Sep 30, 2025 | 11.35 Mn |
| Jun 30, 2025 | 19.98 Mn |
| Jun 30, 2025 | 19.98 Mn |
| Mar 31, 2025 | -5.40 Mn |
| Mar 31, 2025 | -5.40 Mn |
| Dec 31, 2024 | 84.33 Mn |
| Dec 31, 2024 | 84.33 Mn |
| Sep 30, 2024 | -3.95 Mn |
| Sep 30, 2024 | -3.95 Mn |
| Jun 30, 2024 | -1.37 Mn |
| Jun 30, 2024 | -1.37 Mn |
| Mar 31, 2024 | -3.36 Mn |
| Mar 31, 2024 | -3.36 Mn |
| Dec 31, 2023 | 2.67 Mn |
| Dec 31, 2023 | 2.67 Mn |